Ethinylestradiol and testosterone have divergent effects on circulating IGF system components in adolescents with constitutional tall stature.
Article Details
- CitationCopy to clipboard
Rooman RP, De Beeck LO, Martin M, van Doorn J, Mohan S, Du Caju MV
Ethinylestradiol and testosterone have divergent effects on circulating IGF system components in adolescents with constitutional tall stature.
Eur J Endocrinol. 2005 Apr;152(4):597-604.
- PubMed ID
- 15817916 [ View in PubMed]
- Abstract
OBJECTIVE: Pharmacological doses of estrogens or testosterone are used to limit the final height of girls or boys with constitutional tall stature but the mechanism behind this growth inhibition is still debated. We therefore studied the changes in the circulating components of the insulin-like growth factor (IGF) system during high dose sex steroid therapy. DESIGN AND METHODS: Twenty three girls and twenty boys with constitutional tall stature were treated with 100 microg ethinylestradiol per day or 250 mg testosterone ester every 14 days respectively. In 19 girls and 18 boys, the levels of IGF-I, free IGF-I, IGF-II, acid-labile subunit (ALS) and IGF binding proteins (IGFBP)-2 to -6 were measured before and 3-6 months after the start of therapy (group 1). In 18 girls and 11 boys, samples were collected at the end of therapy and 3 to 6 months afterwards (group 2). Fourteen girls and nine boys belonged to both groups. All parameters were measured by radioimmunoassay or ELISA. RESULTS: Levels of IGF-I were decreased significantly by estrogen treatment but remained unchanged during testosterone treatment. Free IGF-I decreased during estrogen treatment but increased during testosterone therapy. Estrogens increased IGF-II and testosterone reduced it. The important reduction of IGFBP-2 during estrogen therapy is not reproduced by androgen therapy, neither is the stimulation by estrogens of IGFBP-4. IGFBP-3 is not modulated by either sex steroid. We found that IGFBP-6 is up-regulated by testosterone but not by estrogens; the reverse is true for ALS, which increased during estrogen treatment but remained unchanged during testosterone treatment. CONCLUSIONS: Our findings demonstrate that androgens and estrogens exert differential effects on the circulating levels of several IGF components.
DrugBank Data that Cites this Article
- Pharmaco-proteomics
Drug Drug Groups Gene Gene ID Change Interaction Chromosome Ethinylestradiol Approved IGFBP2 3485 decreased Ethinyl Estradiol results in decreased expression of IGFBP2 protein 2q35 Testosterone Approved Investigational IGF2 3481 decreased Testosterone results in decreased expression of IGF2 protein 11p15.5 Ethinylestradiol Approved IGF2 3481 increased Ethinyl Estradiol results in increased expression of IGF2 protein 11p15.5 Ethinylestradiol Approved IGFALS 3483 increased Ethinyl Estradiol results in increased expression of IGFALS protein 16p13.3 Ethinylestradiol Approved IGFBP4 3487 increased Ethinyl Estradiol results in increased expression of IGFBP4 protein 17q21.2 Testosterone Approved Investigational IGFBP2 3485 increased Testosterone results in increased expression of IGFBP2 protein 2q35 Testosterone Approved Investigational IGFBP6 3489 increased Testosterone results in increased expression of IGFBP6 protein 12q13.13 Ethinylestradiol Approved IGF1 3479 decreased Ethinyl Estradiol results in decreased expression of IGF1 protein 12q23.2 Ethinylestradiol Approved IGF1 3479 decreased Ethinyl Estradiol results in decreased expression of IGF1 protein 12q23.2